European Commission has designated oral decitabine and cedazuridine as orphan drugs for the treatment of Acute myeloid leukemia (AML)
Astex Pharmaceuticals, Inc. today announces that the European Commission (EC) has granted orphan-drug designation to the oral fixed-dose combination of decitabine and cedazuridine for the treatment of ...